한빛사논문 | BRIC

김성배 님의 논문 목록

울산대학교 의과대학, 서울아산병원

CV File 76 kb

Response to letter entitled: Re: Pathologic Complete Responses, Long-term Outcomes, and Recurrence Patterns in HER2-low vs. HER2-zero Breast Cancer after Neoadjuvant Chemotherapy
- Eur. J. Cancer, 2023 Feb;180:186-188 | https://doi.org/10.1016/j.ejca.2022.11.019
- 2023-02
- 의약학
- 한빛사논문
Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy
- Eur. J. Cancer, 2022 Nov;176:30-40 | doi: 10.1016/j.ejca.2022.08.031
- 2022-11
- 의약학
- 한빛사논문
Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study
- Lancet Oncol., Available online 4 March 2019 | https://doi.org/10.1016/S1470-2045(18)30936-7
- 2019-03
- 의약학
- 한빛사논문
- 김성배(울산대학교 의과대학, 서울아산병원)
[Correspondence]Concordance between plasma-based and tissue-based next-generation sequencing in LOTUS
- Lancet Oncol., Volume 18, Issue 11, November 2017, Pages e638 | https://doi.org/10.1016/S1470-2045(17)30785-4
- 2017-11
- 의약학
- 한빛사논문
- 김성배(울산대학교 의과대학, 서울아산병원)
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- Lancet Oncol., Volume 18, Issue 10, October 2017, Pages 1360-1372 | https://doi.org/10.1016/S1470-2045(17)30450-3
- 2017-08
- 의약학
- 한빛사논문, 상위피인용논문
A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma
- Ann. Oncol., 15 (6): 947-954, June 2004, doi: 10.1093/annonc/mdh219
- 2004-06
- 의약학
- 상위피인용논문

저자논문

저자논문

저자논문

저자논문

CV 열람하기

연락처 보기